Rx0000521 |
La Jolla Pharmaceutical Company |
04/29/2025 |
68547050102 |
Giapreza 2.5 mg/mL SDV Injection, Intravenous |
01/02/2025 |
145.00 |
1765.00 |
01/06/2037 |
Single Source Drug |
None |
None |
None |
1 |
Our drugs target rare diseases and serve smaller patient populations, meaning that the costs of development and manufacturing must be spread over fewer patients, leading to the need for higher prices. Our comprehensive evaluation included other similar drugs and we compared that analysis with pharmacoeconomics to make the decision to raise our price. |
None |
A change or improvement in the product does not necessitate the price increase. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000089 |
Lannett Company, Inc. |
04/25/2025 |
54838050280 |
HydrOXYzine HCl, 10 mg/5 mL Solution, 473 mL bottle |
01/21/2025 |
19.26 |
115.56 |
None |
Non-innovator Multiple Source Drug |
None |
None |
None |
1 |
The change in WAC price reflects the increased cost to supply efficiently to patients due to recent API increase for this molecule incremental supply chain and manufacturing expense and marketing costs. |
None |
No change or improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994001116 |
DEFINITY US 16Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 16 VIAL, GLASS in 1 CARTON (11994-011-16) > 1.5 mL in 1 VIAL, GLASS |
01/01/2025 |
348.76 |
5714.35 |
05/04/2037 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994001104 |
DEFINITY US 4Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 4 VIAL, GLASS in 1 CARTON (11994-011-04) > 1.5 mL in 1 VIAL, GLASS |
01/01/2025 |
90.51 |
1483.01 |
05/04/2037 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994009136 |
LEU TechneLite® (Technetium Tc99m Generator) 1000 Ci 50 MIL/ML INJ 1 vial |
01/01/2025 |
237.04 |
4187.72 |
07/01/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994009109 |
LEU TechneLite® (Technetium Tc99m Generator) 10000 Ci 50 MIL/ML INJ 1 vial |
01/01/2025 |
805.64 |
14232.95 |
07/01/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994009110 |
LEU TechneLite® (Technetium Tc99m Generator) 12500 Ci 50 MIL/ML INJ 1 vial |
01/01/2025 |
947.22 |
16734.19 |
07/01/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994009111 |
LEU TechneLite® (Technetium Tc99m Generator) 15000 Ci 50 MIL/ML INJ 1 vial |
01/01/2025 |
1165.08 |
20583.07 |
07/01/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994009112 |
LEU TechneLite® (Technetium Tc99m Generator) 18000 Ci 50 MIL/ML INJ 1 vial |
01/01/2025 |
1433.04 |
25317.12 |
07/01/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994009173 |
LEU TechneLite® (Technetium Tc99m Generator) 2000 Ci 50 MIL/ML INJ 1 vial |
01/01/2025 |
299.08 |
5283.81 |
07/01/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994009192 |
LEU TechneLite® (Technetium Tc99m Generator) 2500 Ci 50 MIL/ML INJ 1 vial |
01/01/2025 |
328.79 |
5808.70 |
07/01/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994009101 |
LEU TechneLite® (Technetium Tc99m Generator) 3000 Ci 50 MIL/ML INJ 1 vial |
01/01/2025 |
368.33 |
6507.20 |
07/01/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994009103 |
LEU TechneLite® (Technetium Tc99m Generator) 4000 Ci 50 MIL/ML INJ 1 vial |
01/01/2025 |
430.32 |
7602.35 |
07/01/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994009104 |
LEU TechneLite® (Technetium Tc99m Generator) 4500 Ci 50 MIL/ML INJ 1 vial |
01/01/2025 |
464.67 |
8209.16 |
07/01/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994009105 |
LEU TechneLite® (Technetium Tc99m Generator) 5000 Ci 50 MIL/ML INJ 1 vial |
01/01/2025 |
500.32 |
8839.05 |
07/01/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994009106 |
LEU TechneLite® (Technetium Tc99m Generator) 6000 Ci 50 MIL/ML INJ 1 vial |
01/01/2025 |
565.11 |
9983.60 |
07/01/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994009107 |
LEU TechneLite® (Technetium Tc99m Generator) 7500 Ci 50 MIL/ML INJ 1 vial |
01/01/2025 |
662.05 |
11696.22 |
07/01/2029 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000009 |
Lantheus Medical Imaging, Inc. |
04/08/2025 |
11994000602 |
NEUROLITE® (Kit for the Preparation of Technetium Tc99m Bicisate for Injection) |
01/01/2025 |
213.57 |
7332.65 |
11/23/2008 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
This information is confidential and proprietary, and not publicly available or within the public domain |
Rx0000413 |
Leadiant Biosciences, Inc. |
04/03/2025 |
54482002002 |
Cystaran Ophthalmic Solution 0.44 %, 15ML, Unit-of-Use, Single Bottle |
01/01/2025 |
424.64 |
2597.00 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000413 |
Leadiant Biosciences, Inc. |
04/03/2025 |
54482005401 |
Matulane Oral Capsule 50 MG, 100 Each, Single Bottle |
01/01/2025 |
1925.36 |
14852.00 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000276 |
LEO Pharma Inc. |
04/18/2025 |
50222034604 |
Adbry (tralokinumab-ldrm) solution injection, 150 mg/mL, 2 cartons in 1 multipack > 2 syringes in 1 carton > 1 mL in 1 syringe |
01/01/2025 |
230.34 |
4069.37 |
01/09/2027 |
Single Source Drug |
None |
None |
None |
1 |
LEO increased the price due to increasing competition and a growing utilization of our product in once monthly dosing. This is additionally supported by the new major market competitor with a similar clinical mechanism of action in IL 13 at once monthly maintenance dosing, which is priced significantly higher. LEO Pharmas Adbry syringe still continues to be the lowest net cost price product in the Atopic Dermatitis category. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
LEO Pharma A/S, the Danish parent company of LEO Pharma, entered into a license and royalty agreement with AstraZeneca on June 30, 2016 for the exclusive, global rights to tralokinumab in atopic dermatitis and any future dermatology indications. |
Rx0000276 |
LEO Pharma Inc. |
04/18/2025 |
50222034602 |
Adbry (tralokinumab-ldrm) solution injection, 150 mg/mL, 2 syringes in 1 carton > 1 mL in 1 syringe |
01/01/2025 |
115.17 |
2034.69 |
01/09/2027 |
Single Source Drug |
None |
None |
None |
1 |
LEO increased the price due to increasing competition and a growing utilization of our product in once monthly dosing. This is additionally supported by the new major market competitor with a similar clinical mechanism of action in IL 13 at once monthly maintenance dosing, which is priced significantly higher. LEO Pharmas Adbry syringe still continues to be the lowest net cost price product in the Atopic Dermatitis category. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
LEO Pharma A/S, the Danish parent company of LEO Pharma, entered into a license and royalty agreement with AstraZeneca on June 30, 2016 for the exclusive, global rights to tralokinumab in atopic dermatitis and any future dermatology indications. |
Rx0000025 |
Lundbeck LLC |
04/29/2025 |
67386031401 |
Onfi 10mg. 100 Tablets |
01/02/2025 |
149.08 |
3130.68 |
None |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
"Brain health is Lundbecks sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000025 |
Lundbeck LLC |
04/29/2025 |
67386031501 |
Onfi 20mg. 100 Tablets |
01/02/2025 |
298.16 |
6261.30 |
None |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
"Brain health is Lundbecks sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000025 |
Lundbeck LLC |
04/29/2025 |
67386013051 |
Vyepti 100mg/ml single dose vial |
01/02/2025 |
60.32 |
1888.15 |
None |
Single Source Drug |
None |
None |
None |
1 |
"Brain health is Lundbecks sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies." |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |